Jones Trading Reiterates Buy Rating on PRQR
Jones Trading reaffirmed its Buy rating on PRQR, setting a $10 target, a 538.98% upside from the current price.
Key Points
- On June 26, 2026, Jones Trading reiterated its Buy rating on PRQR, setting a $10 price target.
- Jones Trading's $10 price target implies 538.98% upside from ProQR Therapeutics N.V.'s ($PRQR) current $1.56 share price.
- PRQR shares traded at $1.56 on Friday, with peers like Adage Capital holding 6.25 million shares.
- Insider Hinsch Gylvin Lykke bought 14,495 shares on June 2, 2026, while Chardan Capital also maintains a Buy rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jones Trading, through analyst Catherine Novack, reiterated its Buy rating on PRQR on June 26, 2026. The firm set a price target of $10, showing confidence in the stock's potential. PRQR shares traded at $1.56 on Friday.
Jones Trading vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in PRQR
Adage Capital Partners GP, L.L.C. held steady with 6,253,467 shares valued at approximately $10.1 million. Privium Fund Management B.V. added 109,387 shares, bringing its total to 5,467,149 shares worth about $8.86 million, marking a 2% increase. Aberdeen Group PLC increased its stake by 366,289 shares to 3,316,965 shares, valued around $5.37 million, reflecting a 12.4% boost. Meanwhile, SIO Capital Management, LLC reduced its holdings by 209,466 shares, ending with 1,954,715 shares worth roughly $3.17 million.
Insider Buying and Selling at ProQR Therapeutics N.V.
On June 2, 2026, insider Hinsch Gylvin Lykke purchased 14,495 shares of PRQR. The transaction was not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 26, 2026, Chardan Capital maintained its Buy rating with a $3 price target, while Jones Trading reiterated a Buy with a $10 target. The consensus among analysts remains positive, with a Buy recommendation and multiple firms setting targets between $3 and $10.
About PRQR
PRQR, operating in the biotechnology sector, focuses on developing innovative treatments for genetic disorders. The company's research and development efforts aim to address unmet medical needs through advanced genetic therapies. With a dedicated team, PRQR strives to bring new solutions to market that can significantly improve patient outcomes.
Bottom Line
Jones Trading's reiterated Buy rating and $10 target for PRQR highlights investor interest in the company's potential. As with all 13F filings and analyst reports, these insights reflect past data and should be considered accordingly. Investors often track such updates for trends and sentiment in the market.
Get ProQR Therapeutics N.V. alerts
New 13F filings, insider trades, and analyst moves on $PRQR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.